PMGC Holdings Inc. Announces Updates on Subsidiaries NorthStrive Biosciences and AGA Precision Systems

PMGC Holdings Inc. (NASDAQ:ELAB) has issued two significant press releases. The first, dated December 17, 2025, announces that its subsidiary NorthStrive Biosciences has advanced its AI-driven drug discovery program with Yuva Biosciences to Phase III. This phase focuses on experimental validation of drug compounds identified by YuvaBio's AI platform, MitoNova™, targeting muscle preservation and obesity-related metabolic conditions. The second press release, dated December 22, 2025, reports that another subsidiary, AGA Precision Systems LLC, has achieved AS9100 certification, a key quality standard for the aerospace, defense, and space industries. This certification is expected to strengthen AGA's position and support more complex programs. AGA is also exploring the integration of humanoid robotics and advanced automation into its manufacturing processes. PMGC Holdings Inc. is a diversified holding company with a portfolio including these subsidiaries, aiming for long-term growth through strategic acquisitions and development.